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license (http://creativeexpert centers with long delays in diagnosis leading to significant burden to patients and caregivers.
Although consensus criteria have excellent specificity, there is no standardized way to assess symp-
toms reducing sensitivity.We developed the Lewy body composite risk score (LBCRS) from autopsy-
verified cases to improve the ability to detect DLB in clinic and research populations.
Methods: The LBCRS was tested in a consecutive series of 256 patients compared with the clinical
dementia rating and gold standard measures of cognition, motor symptoms, function, and behavior.
Psychometric properties including floor and ceiling effects; concurrent, construct, and known-groups
validity; and internal consistency of the LBCRS were determined. Receiver operator characteristic
(ROC) curves assessed the ability of LBCRS to differentiate (1) DLB from Alzheimer’s disease
(AD), (b) DLB from all dementia, and (c) mild cognitive impairment (MCI) due to DLB from
MCI due to AD. The LBCRS was completed independent of the clinical evaluation.
Results: Mean LBCRS scores were significantly different between DLB and AD (6.1 6 2.0 vs.
2.4 6 1.3, P , .001) and between MCI-DLB versus MCI-AD (3.2 6 0.9 vs. 1.0 6 0.8, P , .001).
The LBCRS was able to discriminate DLB from other causes of dementia. Using a cutoff score of
3, areas under ROC for DLB versus AD 5 0.93 (0.89–0.98) and for MCI-DLB versus MCI-
AD 5 0.96 (0.91–1.0).
Discussion: The LBCRS increases diagnostic probability that Lewy body pathology is contributing
to the dementia syndrome and should improve clinical detection and enrollment for clinical trials.
 2015 The Author. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Lewy body dementia; Alzheimer’s disease; Mild cognitive impairment; Clinical trials1. Introduction
The Lewy body dementias, composed of two related dis-
orders: dementia with Lewy bodies (DLB) [1] and Parkin-
son’s disease dementia (PDD) [2], are a challenge to
diagnose, particularly outside of expert centers [3]. One of
the great challenges in differential diagnosis of neurodegen-
erative disorders is attributing clinical symptoms to specific
pathologies to guide treatment choices and discuss prognosis
and clinical course [4,5]. Although PDD provides author. Tel.: 11-561-297-4793; Fax: 11-561-297-
lvinj@health.fau.edu
16/j.dadm.2015.05.004
he Author. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).potentially easier route to diagnosis because the cognitive
disorder begins in face of an established movement
disorder [2] and criteria have defined a mild cognitive
impairment (MCI) state [6], DLB is a more difficult entity
to diagnose with delays in diagnosis approaching 18 months
[7] leading to significant burden to patients and caregivers
[8–10]. Patients with dementia are often misdiagnosed
[7,11] with a neurologist finally establishing a diagnosis of
DLB or PDD in 62% of cases [7]. Although consensus
criteria for DLB [1] have excellent specificity (79%–
100%) [12], there is no standardized way to assess or oper-
ationalize many of the cognitive and behavioral symptoms
which markedly decrease sensitivity in clinical practice
(range 12%–88%) [12,13].imer’s Association. This is an open access article under the CC BY-NC-ND
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assist in the diagnosis of PDD, we developed the Lewy
body composite risk score (LBCRS) [14] to improve the
ability to detect DLB and PDD in clinic and research popu-
lations and increase the likelihood of determining whether
Lewy bodies are contributing pathology to the cognitive
diagnosis. The LBCRS was derived from clinical features
in autopsy-verified cases of healthy controls, Alzheimer’s
disease (AD), DLB, and Parkinson’s disease with and
without dementia [15]. Features that predicted Lewy bodies
at autopsy included extrapyramidal signs, cognitive fluctua-
tions, hallucinations, and sleep disturbances [15]. The
LBCRS was initially validated in a research sample with
excellent psychometric properties demonstrating discrimi-
nation between AD and DLB cases with an area under
the curve (AUC) of 96.8% (95% confidence interval
[CI], 0.93–1.0) [14]. A cutoff score of 3 provided a sensi-
tivity of 90% and a specificity of 87%. Here, we present
the psychometric evaluation of the LBCRS in a well-
characterized clinic sample.2. Methods
2.1. Study participants
Participants were drawn from a consecutive series of 256
referrals to the Pearl I. Barlow Center for Memory Evalua-
tion and Treatment, a dementia specialty practice at NYU
Medical Center, from September 2013 to December 2014.
Assessments were completed by a transdisciplinary team
of a neurologist, geriatric nurse practitioner, social worker,
and psychometrician, and all components of the assessment
were part of standard of care at our center [16]. The LBCRS
was completed by the author after the entire evaluation was
performed. During the 75–90 minute office visit, the patient
and caregiver underwent a comprehensive evaluation
including the clinical dementia rating (CDR) and its sum
of boxes (CDR-SB) [17], mood, neuropsychological testing,
caregiver ratings of behavior and function, and caregiver
burden and depression. This study was approved by the
NYU Langone Medical Center Institutional Review Board.
2.2. Clinical assessment
Independent semi-structured interviews were conducted
with the patient and a collateral source. The CDR [17] was
used to determine the presence or absence of dementia and
to stage its severity. The CDR rates cognitive function in
six categories (memory, orientation, judgment and problem
solving, performance in community affairs, home and
hobbies, and personal care); a global CDR 0 indicates no de-
mentia; CDR 0.5 represents MCI or very mild dementia;
CDR 1, 2, or 3 corresponds to mild, moderate, or severe de-
mentia. Diagnoses were determined using published clinical
criteria for MCI due to AD [18], AD [19], DLB [1] fronto-
temporal degeneration (FTD) [20,21], and vascular
dementia (VaD) [22]. Research criteria were used fordefining MCI due to DLB [22–25]. Extrapyramidal
features were assessed with the Movement Disorders
Society-Unified Parkinson’s Disease Rating Scale, motor
subscale part III (UPDRS) and a modified Hoehn and Yahr
stage was assigned [26]. The Charlson comorbidity index
[27] was completed to assess the potential impact of comor-
bid medical conditions on the patient’s cognitive status.
2.3. Caregiver evaluation
Caregivers completed evaluations to determine the pres-
ence and severity of noncognitive symptoms observed in
the patient and their impact on the caregiver. The neuropsy-
chiatric inventory (NPI) [28] assessed behavior, Mayo
fluctuation questionnaire (MFQ) [29] assessed presence
of cognitive fluctuations, and Epworth Sleepiness Scale
(EES) [30] assessed daytime sleepiness. The Mayo sleep
questionnaire (MSQ) [31] assessed the presence of parasom-
nias, particularly rapid eye movement sleep behavior disor-
der (RBD). A caregiver rating of daytime alertness was
collected using a 1-10 Likert scale [31]. The functional ac-
tivities questionnaire [32] was used to rate performance of
activities of daily living. The Zarit burden inventory [33]
evaluated caregiver burden and the personal health question-
naire [34] assessed caregiver depression.
2.4. Neuropsychological evaluation
Each patient was administered a 30-minute test battery at
the time of the office visit to assess their cognitive status. The
psychometrician was unaware of the diagnosis, CDR stage,
or LBCRS. A brief global assessment was performed using
the mini mental state examination (MMSE) [35]. The battery
included measures of episodic memory (Hopkins verbal
learning task) [36]; semantic memory (animal fluency)
[37] and 15-item Boston naming test [38]; and working
memory (letter-number sequencing) [39]. Two-timed mea-
sures addressed psychomotor and executive abilities: trail
making A and trail making B [40]. Construction was as-
sessed with the clock drawing task [41]. Mood was assessed
with the hospital anxiety depression scale [42] providing
subscale scores for depression (HADS-D) and anxiety
(HADS-A).
2.5. Completion of the LBCRS
The LBCRS (Table 1) was not considered during the clin-
ical assessment or diagnosis. The LBCRS was completed af-
ter all other rating scales were scored and the diagnosis
presented to the patient and family. Data were taken from
the patient charts to complete the LBCRS with questions
1–4 taken from the UPDRS, question 5 from the ESS, ques-
tions 6–7 from theMFQ, question 8 from the NPI, question 9
from the MSQ, and question 10 from physical findings and
complaints of the patient. The operationalization of physical
findings as being present for at least 6 months or symptoms
occurring at least three times over the past 6 months
Table 1
Lewy body composite risk score
Please rate the following physical findings being present or
absent for the past 6 mo and symptoms as being present or
absent for at least 3 times over the past 6 mo.
Does the patient. Yes No
Have slowness in initiating and maintaining movement or
have frequent hesitations or pauses during movement?
Have rigidity (with or without cogwheeling) on passive
range of motion in any of the 4 extremities?
Have a loss of postural stability (balance) with or without
frequent falls?
Have a tremor at rest in any of the 4 extremities or head?
Have excessive daytime sleepiness and/or seem drowsy and
lethargic when awake?
Have episodes of illogical thinking or incoherent, random
thoughts?
Have frequent staring spells or periods of blank looks?
Have visual hallucinations (see things not really there)?
Appear to act out his/her dreams (kick, punch, thrash, shout
or scream)?
Have orthostatic hypotension or other signs of autonomic
insufficiency?
Total score
Copyright 2013 The Lewy Body Composite Risk Score James E. Galvin,
MD, MPH.
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signs and symptoms rated as present.2.6. Statistical analyses
Analyses were conducted in SPSS version 21 (Armonk,
NY). Descriptive statistics were used to present demo-
graphic and clinical characteristics of patients, informant
ratings, LBCRS, CDR, CDR-SB, and neuropsychological
testing. One-way analysis of variance (ANOVA) was used
for continuous data, and chi-square analyses were used for
categorical data. Concurrent validity was assessed
comparing the strength of association between LBCRS
scores and other clinical scales using Pearson correlation co-
efficients. The partial eta-squared (h2) from the omnibus
ANOVAwas used to estimate effect size. To assess item vari-
ability, the item frequency distributions, range, and standard
deviations were calculated. Item and scale scores were
examined for floor and ceiling effects (i.e., clustering of par-
ticipants at the best and worst possible scores, respectively).
Principal components analyses using Varimax rotation were
performed to explore the underlying factor structure of the
LBCRS [43]. To determine the range of scores measured
by the LBCRS and subscales, the observed score range
and measures of central tendency and variability were
computed. Internal consistency was examined as the propor-
tion of the variability in the responses that is the result of dif-
ferences in the respondents. Internal consistency was
reported as the Cronbach a reliability coefficient. Coeffi-
cients .0.7 are good measures of internal consistency
[44]. Receiver operator characteristic (ROC) curves wereused to assess the discriminative ability of LBCRS to differ-
entiate (a) DLB from AD; (b) DLB from all dementia, and
(c) MCI due to DLB from MCI due to AD reported as the
AUC with 95% confidence intervals. Sensitivity, specificity,
positive (PPV) and negative (NPV) predictive values, and
likelihood ratios were reported. The likelihood ratio of any
screening test is the probability that a positive test is found
in persons with disease divided by the probability of the
same finding in persons without disease [45]. Likelihood ra-
tios range from 0 to infinity, with larger numbers providing
more convincing evidence of disease; smaller numbers
argue that disease is less likely [45]. Ratios close to 1 lack
diagnostic value. Known-groups validity was assessed
comparing the mean performance between groups (DLB
vs. AD; MCI due to DLB vs. MCI due to AD) [46].3. Results
3.1. Sample characteristics
The cohort had a mean age of 77.8 6 8.2 years (range,
50–98 years) with a mean education of 15.5 6 3.5 years
(range, 4–24 years), and 53% female. The sample race/
ethnicity was 89.8% white, non-Hispanic; 4.3% African-
American, non-Hispanic; 4.7% Hispanic; and 1.2% Asian.
Informants were 53.9% spouses and 46.1% nonspouse care-
givers (adult children, friends, and other relatives). The
mean MMSE score of the sample was 21.7 6 6.3 (range,
0–30), and the Charlson comorbidity index [27] was
2.2 6 1.4 (range, 0–9). Diagnoses include no cognitive
impairment (n 5 8), MCI (n 5 71), AD (n 5 100), DLB
(n 5 53), VaD (n 5 5), FTD (n 5 10), and other dementias
(n5 9). Of those with MCI, 57 were thought to be due to AD
[18] and 14 were thought to be due to DLB [23–25]. Sample
characteristics, neuropsychological performance, ratings,
and LBCRS scores by diagnosis are shown in Table 2.
Table 3 demonstrates the strength of association between
the LBCRS and clinical indices and tests of cognition,
behavior, and function. Higher LBCRS scores were gener-
ally highly correlated with poorer performance and worse
health ratings.
3.2. Reliability and scale score features of the LBCRS
Principal component analysis revealed two domains. A
motor domain (Eigenvalue 3.1; 31.8% variance) consisted
of the clinical signs of bradykinesia, rigidity, tremor, and
postural instability. A nonmotor domain (Eigenvalue 1.3;
13.1% variance) consisted of the clinical symptoms of day-
time sleepiness, illogical or incoherent thoughts, staring
spells, hallucinations, RBD, and autonomic insufficiency
(e.g., orthostatic hypotension, chronic constipation, sialor-
rhea) [47]. Table 4 demonstrates the inter-item and
item-total correlations for the LBCRS as well as the factor
loadings. The degree to which the LBCRS was free from
random error was assessed using Cronbach a for the total
score, motor factor, and nonmotor factor (Table 5). The
Table 2
Sample characteristics
Characteristics
Dementia MCI
AD (n 5 100) DLB (n 5 53) P value 2 AD (n 5 57) 2 DLB (n 5 14) P value
Clinical features
Age, y 79.9 (7.6) 78.6 (7.6) .32 76.1 (8.9) 77.6 (9.1) .59
Gender, % male 40.0 62.3 .009 43.9 57.1 .37
Education, y 15.2 (3.9) 14.5 (3.6) .29 15.8 (2.9) 16.1 (3.0) .70
CDR-SB 5.8 (3.3) 8.9 (5.1) ,.001 1.8 (0.9) 2.4 (1.0) .04
CDR 0.9 (0.5) 1.5 (0.9) ,.001 0.5 (0.1) 0.5 (0.0) .99
Charlson comorbidity index 2.3 (1.3) 2.4 (1.5) .63 1.9 (1.2) 2.2 (1.7) .42
Systolic BP, sitting, mm Hg 132.8 (18.9) 125.4 (22.4) .04 135.6 (19.0) 139.4 (25.0) .54
Systolic BP, standing, mm Hg 132.6 (18.4) 123.5 (22.7) .02 133.2 (18.7) 137.0 (22.1) .35
Mini-physical performance test 9.8 (2.6) 8.4 (3.1) .02 11.8 (2.6) 10.5 (3.5) .14
Functional activities questionnaire 10.7 (8.7) 17.4 (10.1) ,.001 3.4 (4.0) 5.7 (5.6) .10
UPDRS III 7.3 (8.7) 33.3 (22.3) ,.001 1.2 (2.3) 9.8 (12.4) ,.001
Hoehn and Yahr stage 0.4 (1.1) 2.7 (1.4) ,.001 0.0 (0.0) 0.7 (1.0) ,.001
Presence of Parkinsonism, % 26.0 87.0 ,.001 0 35.7 ,.001
Bradykinesia 57.3 91.3 ,.001 14.8 57.1 .001
Rigidity 6.3 71.1 ,.001 0 7.1 .05
Tremor 7.3 34.8 ,.001 0 7.1 .05
Postural Instability 27.1 76.1 ,.001 0 28.6 ,.001
FAQ 10.7 (8.7) 17.4 (10.1) ,.001 3.4 (4.0) 5.7 (5.6) .10
Neuropsychological features
MMSE 19.6 (5.5) 18.0 (7.6) .15 25.9 (3.6) 26.6 (2.9) .46
Animal naming 8.3 (4.0) 8.8 (4.3) .83 16.7 (5.8) 13.8 (5.6) .09
Boston naming test 7.6 (4.2) 8.8 (4.2) .12 11.3 (3.1) 12.5 (1.5) .19
HTLV—total 9.9 (4.7) 9.8 (4.4) .79 15.8 (4.3) 15.9 (4.3) .92
HTLV—delayed 0.5 (1.3) 0.9 (1.6) .13 2.7 (2.4) 2.8 (3.0) .82
HTLV—cued 4.7 (3.4) 5.8 (2.9) .09 9.1 (1.9) 9.5 (1.8) .57
Letter-number sequencing, % impaired 66.7 95.0 .01 62.8 45.5 .29
Trail making A, s 81.8 (47.3) 101.4 (53.6) .05 40.7 (19.9) 49.6 (26.3) .16
Trail making B, s 168.3 (26.7) 164.8 (32.6) .64 108.3 (41.4) 109.4 (38.3) .93
Clock drawing, % impaired 91.7 88.9 .75 42.1 42.9 .96
Behavioral features
HADS-anxiety 5.4 (3.4) 6.3 (3.6) .59 6.1 (3.7) 6.5 (2.7) .69
HADS-depression 5.7 (3.4) 7.8 (4.2) .004 5.3 (3.6) 5.4 (2.9) .96
NPI-Q 7.7 (5.8) 11.6 (5.7) ,.001 5.0 (4.4) 7.7 (5.6) .06
Mayo fluctuation questionnaire 1.6 (1.1) 2.9 (0.9) ,.001 1.1 (0.9) 2.1 (1.5) .003
Epworth sleepiness scale 6.9 (4.9) 9.7 (5.2) .001 6.7 (4.5) 8.9 (4.7) .12
Alertness rating 7.2 (2.0) 5.6 (1.8) ,.001 7.9 (1.6) 6.1 (2.0) .001
Hallucinations, % 8.4 47.8 ,.001 1.9 7.1 .30
Misidentifications, % 1.1 34.8 ,.001 0 14.3 .005
Capgras delusions, % 1.1 17.4 ,.001 0 0 —
RBD, % 5.3 41.5 ,.001 3.6 35.7 ,.001
Fluctuations, % 43.9 92.2 ,.001 32.7 42.9 .48
Lewy body composite risk scores
Total score 2.4 (1.3) 6.1 (2.0) ,.001 1.0 (0.8) 3.2 (0.9) ,.001
Factor 1 (motor) 1.0 (1.0) 2.8 (1.0) ,.001 0.1 (0.8) 1.1 (1.1) ,.001
Factor 2 (nonmotor) 1.5 (1.0) 3.4 (1.5) ,.001 1.0 (0.8) 2.1 (1.2) .001
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; CDR-SB, clinical dementia rating and its sum
of boxes; CDR, clinical dementia rating; BP, blood pressure; UPDRS III, unified Parkinson’s disease rating score–part III, motor; FAQ, functional assessment
questionnaire; MMSE, mini mental state examination; HTLV, Hopkins verbal learning task; HADS, hospital anxiety and depression scale; NPI, neuropsychi-
atric inventory; RBD, rapid eye movement sleep behavior disorder.
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(a5 0.71) and motor (a5 0.73) scores. The internal consis-
tency for the nonmotor was lower (a 5 0.57), likely reflect-
ing the varied constructs contained within this factor. The
LBCRS covered the entire range of possible scores, and
the mean, median, and standard deviation demonstrated a
sufficient dispersion of scores for the assessing and moni-
toring the presence and severity of dementia with low per-centage of missing data. There were very low ceiling
effects (1.3–2.4), and floor effects (9.4–29.9) showed good
separation between groups, especially for motor domain
questions. The two factors (motor and nonmotor) were
moderately correlated suggesting they are related but sub-
stantially distinct. The total LBCRS was internally consis-
tent with scale score features that demonstrated ample
dispersion of scores for both the LBCRS total score and
Table 3
Mean performance on rating scales and neuropsychological tests and
concurrent validity with the LBCRS
Measure Mean (SD) R P value
Age, y 77.7 (8.3) 0.07 .26
Education, y 15.3 (3.6) 20.14 .03
CDR-SB 5.2 (4.4) 0.62 ,.001
CDR 0.9 (0.7) 0.60 ,.001
Charlson comorbidity index 2.2 (1.4) 0.08 .23
Systolic BP, sitting, mm Hg 133.2 (21.1) 20.23 .001
Mean arterial pressure, sitting 94.5 (12.9) 20.24 .001
Systolic BP, standing, mm Hg 131.9 (20.8) 20.21 .005
Mean arterial pressure, standing 94.3 (11.1) 20.21 .003
Body mass index 25.8 (4.5) 20.04 .56
Mini-PPT 10.3 (2.9) 20.39 ,.001
UPDRS III 12.5 (18.0) 0.78 ,.001
Hoehn and Yahr Stage 0.9 (1.6) 0.79 ,.001
FAQ 9.8 (9.5) 0.61 ,.001
MMSE 21.8 (6.3) 20.41 ,.001
Animal naming 11.2 (6.1) 20.41 ,.001
Boston naming test 9.3 (4.2) 20.12 .08
HTLV—total 12.4 (5.5) 20.34 ,.001
HTLV—delayed 1.6 (2.4) 20.23 .001
HTLV—cued 6.8 (3.5) 20.22 .002
Trail making A, s 68.8 (46.5) 0.40 ,.001
Trail making B, s 140.8 (44.6) 0.24 .001
HADS—anxiety 5.9 (3.5) 0.05 .51
HADS—depression 6.1 (3.8) 0.15 .03
NPI-Q 7.9 (5.9) 0.49 ,.001
Mayo fluctuation questionnaire 1.8 (1.3) 0.71 ,.001
Epworth sleepiness scale 7.4 (4.8) 0.35 ,.001
Alertness rating 7.0 (2.0) 20.53 ,.001
Caregiver burden 16.8 (10.1) 0.27 ,.001
Caregiver depression 2.1 (2.7) 0.15 .08
Abbreviations: LBCRS, Lewy body composite risk score; SD, standard
deviation; CDR-SB, clinical dementia rating and its sum of boxes; CDR,
clinical dementia rating; BP, blood pressure; PPT, physical performance
test; UPDRS, unified Parkinson disease rating scale; FAQ, functional activ-
ities questionnaire; MMSE, mini mental state examination; HVLT, Hopkins
verbal learning test; HADS, hospital anxiety and depression scale; NPI,
neuropsychiatric inventory.
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nonmotor factor (R 5 0.29, P , .001) were correlated with
increasing caregiver burden. The LBCRS was not associated
with increased caregiver depression.Table 4
LBCRS inter-item correlations, item-total correlations, and factor loadings
LBCRS inter-item correlation matrix
B R PI T DS IL
Bradykinesia (B) 1
Rigidity (R) 0.36 1
Postural instability (PI) 0.45 0.57 1
Tremor (T) 0.25 0.47 0.35 1
Daytime sleepiness (DS) 0.12 0.26 0.22 0.12 1
Illogical thoughts (IT) 0.02 0.13 0.09 0.04 0.14 1
Staring spells (SS) 0.11 0.18 0.15 0.05 0.18 0.25
Hallucinations (H) 0.24 0.39 0.38 0.27 0.17 0.22
RBD 0.02 0.24 0.14 0.21 0.21 0.09
Autonomic (OH) 0.17 0.41 0.21 0.11 0.18 0.08
Abbreviation: LBCRS, Lewy body composite risk score.3.3. Known-groups validity of the LBCRS
The extent to which the LBCRS total and subscales
separate the known groups of cognitive impairment,
defined by an independent evaluation, is evidence of
known-group validity (Table 2) [46]. ANOVA p-tests
demonstrated that mean LBCRS total scores were signifi-
cantly different between DLB and AD (F 5 170.1;
P , .001) as was the motor factor (F 5 73.8; P , .001)
and nonmotor factor (F 5 55.5; P , .001). The LBCRS
scores were also significantly different between MCI due
to AD versus MCI due to DLB for the total score
(F 5 78.1; P , .001), motor factor (F 5 26.4;
P , .001) and nonmotor factor (F 5 12.5; P 5 .001).
The effect size of the LBCRS, based on partial h2 values,
demonstrated that group membership was well-defined by
total LBCRS (h2 5 0.73), motor factor (h2 5 0.58), and
nonmotor factor (h2 5 0.43). The characteristics of the
LBCRS total score and individual questions by different
dementia etiologies are demonstrated in Table 6. The
LBCRS discriminated DLB from nearly all other dementia
causes. Two VaD patients had significant vascular parkin-
sonism (UPDRS scores of 26 and 70) but had negative
dopamine transporter scans and no response to levodopa
replacement. Two other dementia patients had notable
parkinsonism due to (1) severe developmental disorder
and (2) normal pressure hydrocephalus.3.4. Discriminative ability of the LBCRS
ROC curves were generated to measure the effective-
ness of the LBCRS to discriminate between cognitive
impairment likely due to DLB from other causes of
cognitive impairment (Table 7). Using the cutoff of 3
(identical to the developmental research sample), the
LBCRS was able to discriminate DLB from AD (AUC,
0.94; 95% CI, 0.90–0.97; P , .001) with a sensitivity of
94.2%, specificity of 78.2%, PPV of 68.3%, and NPV of
95.8%. The likelihood ratio of a positive test was 4.1,
and the likelihood ratio of a negative test was 0.08.
These data support the LBCRS should greatly facilitateItem-total
correlation
Factor loading
SS H RBD OH Motor Nonmotor
0.56 0.70
0.69 0.75
0.64 0.78
0.53 0.66
0.53 0.46
0.45 0.56
1 0.47 0.60
0.20 1 0.64 0.51
0.15 0.30 1 0.49 0.62
0.19 0.35 0.39 1 0.48 0.58
Table 5
LBCRS features: Internal consistency reliability, score distributions, and interscore correlations
Domain Items
Reliability
Cronbach a (95% CI)
Score features and distribution
% floor % ceiling
Interscale correlation
Spearman r
Range Mean Median SD Motor Nonmotor Total
Motor 4 0.73 (0.66–0.79) 0–4 1.2 1.0 1.3 29.9 6.0 1
Nonmotor 6 0.57 (0.47–0.67) 0–6 1.8 2.0 1.4 11.5 1.7 0.39 1
Total 10 0.72 (0.65–0.77) 0–10 2.9 2.0 2.3 9.4 1.3 0.81 0.85 1
Abbreviations: LBCRS, Lewy body composite risk score; CI, confidence interval; SD, standard deviation.
NOTE. % floor is the percentage of patients with the lowest (best) possible score. % ceiling is the percentage of patients with the highest (worst) possible score.
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etiologies. Using the same cutoff of 3, the LBCRS was
also able to discriminate DLB from any dementia (AUC,
0.94; 95% CI, 0.91–0.98; P , .001) with a sensitivity of
97.9%, specificity of 86.1%, PPV of 65.3%, NPV of
99.4%, likelihood ratio of a positive test of 7.0, and likeli-
hood ratio of a negative test of 0.02. Although individually
there were only a few cases of other non-AD dementia, we
explored the ability of the LBCRS to differentiate DLB
from VaD, FTD, and other dementias. The AUC for FTD
was 0.96 (95% CI, 0.92–1.00; P , .001) and for other de-
mentias was 0.89 (95% CI, 0.75–1.00; P , .001). In this
cohort, the LBCRS did not differentiate between DLB
and VaD (AUC 0.73; 95% CI, 0.45–1.00; P 5 .09); howev-
er, 2 of the 5 VaD cases had significant vascular parkin-
sonism which increased the motor factor of the LBCRS
without affecting the nonmotor factor. Finally, the LBCRS
was able to discriminate between two probable etiologies
of MCI (DLB vs. AD) with an AUC 0.96 (95% CI,Table 6
Performance of LBCRS total scores and individual questions across different dem
LBCRS total scores AD n 5 100 LBD n 5 53
Age, y 79.8 (7.5) 78.4 (7.7)
Education, y 15.2 (2.9) 14.5 (3.6)
Gender, % female 58.7 38.9
CDR 1.0 (0.6) 1.5 (0.9)
CDR-SB 5.7 (3.3) 8.8 (5.2)
Charlson comorbidity 2.3 (1.3) 2.4 (1.5)
MMSE 19.6 (5.5) 18.2 (7.7)
FAQ 10.5 (8.5) 17.1 (10.1)
NPI 7.7 (5.7) 11.6 (5.7)
UPDRS III 6.8 (8.6) 32.7 (22.1)
LBCRS total score 2.4 (1.3) 6.1 (2.0)
Bradykinesia, % 54.0 97.6
Rigidity, % 5.7 70.7
Postural instability, % 21.8 70.7
Rest tremor, % 9.2 36.6
Daytime sleepiness, % 60.9 92.7
Illogical thoughts, % 48.3 72.5
Staring spells, % 23.0 55.5
Hallucinations, % 9.2 53.7
RBD, % 4.6 41.5
Autonomic insufficiency, % 1.2 25.0
Abbreviations: LBCRS, Lewy body composite risk score; AD, Alzheimer’s dise
ical dementia rating; CDR-SB, clinical dementia rating and its sum of boxes; MM
UPDRS, unified Parkinson disease rating scale; RBD, rapid eye movement sleep
*Two patients had vascular parkinsonism with negative dopamine transporter S0.91–1.00; P , .001) with a sensitivity of 100%, specificity
of 72.9%, PPV of 46.2%, NPV of 100%, likelihood ratio
of a positive test of 3.2, and likelihood ratio of a negative
test of 0.4. Discussion
We previously used an autopsy-based sample to define
a clinical phenotype for Lewy body dementia [15] and
created a composite risk score that allowed us to opera-
tionalize consensus criteria core, suggestive and support-
ive features of Lewy body dementias to increase the
sensitivity and specificity of the diagnosis [14]. The
LBCRS is a brief rating scale that can be completed by
the clinician and provides structured questions to assess
clinical signs and symptoms highly associated with
underlying pathology. This may be particularly helpful
concerning clinical symptoms for which there are no
broadly accepted methods to assess their presence (i.e.,entia etiologies
VaD n 5 5 FTD n 5 10 Other n 5 9 P value
77.2 (6.2) 72.7 (8.2) 70.2 (7.5) .001
14.8 (3.4) 16.8 (3.3) 16.9 (3.4) .28
100.0 30.0 55.6 .02
1.7 (0.9) 0.8 (0.8) 1.0 (0.8) ,.001
9.3 (6.3) 5.2 (4.7) 5.0 (4.4) ,.001
2.6 (1.1) 2.0 (1.3) 2.3 (2.6) .93
19.7 (6.0) 23.6 (1.4) 26.1 (2.2) .005
16.6 (13.9) 8.1 (9.9) 12.1 (9.9) .001
11.4 (5.6) 10.5 (9.1) 6.9 (4.5) .002
30.5 (27.8) 6.7 (6.4) 4.5 (7.7) ,.001
4.0 (2.9)* 2.4 (0.9) 3.0 (1.9) ,.001
66.7 75.0 66.7 ,.001
0.0 0.0 50.0 ,.001
0.0 12.5 33.3 ,.001
0.0 0.0 16.7 .002
33.3 50.0 83.3 .002
66.7 37.5 50.0 .101
33.3 50.0 33.3 .009
0.0 0.0 16.7 ,.001
0.0 0.0 0.0 ,.001
0.0 0.0 0.0 ,.001
ase; VaD, vascular dementia; FTD, frontotemporal degeneration; CDR, clin-
SE, mini mental state examination; FAQ, functional activities questionnaire;
behavior disorder.
PECT (DAT) scans.
Table 7
Discrimination ability of the LBCRS by receiver operator characteristic curves
Area (95% CI) P value Cutoff score Sensitivity, % Specificity, % PPV NPV LRpos LRneg
DLB versus AD 0.94 (0.90–0.97) ,.001 3 94.2 78.2 68.3 95.8 4.1 0.08
DLB versus any dementia 0.94 (0.91–0.98) ,.001 3 97.9 86.1 65.3 99.4 7.0 0.02
MCI 2 DLB versus 2 AD 0.96 (0.91–1.0) ,.001 2 100.0 72.9 46.2 100.0 3.2 0
Abbreviations: CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; LRpos, likelihood ratio of a positive test; LRneg, likeli-
hood ratio of a negative test; DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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maintaining the brevity (w3 minutes) and simple format
of yes/no questions for use in clinical practice, clinical
research, and epidemiologic projects potentially allevi-
ating the need to perform the large number of validated
scales used to derive the LBCRS. For example, outside
of movement disorder clinics, physicians do not
commonly perform the UPDRS due to the training
required and the length of time to administer—the LBCRS
simply requires the clinician to assess whether the patient
has bradykinesia, rigidity, postural instability, or rest
tremor without having to grade each extremity. Similarly,
the LBCRS provides structured yes/no questions for six
nonmotor features that are present in the large majority
of Lewy body dementia patients but are much less
commonly found in other forms of dementia (Table 2).
These findings hold true even in the MCI cases where
the cognitive tests fail to provide adequate differentiation.
Most patients never receive an evaluation by a neurologist
skilled in the diagnosis of Lewy body dementia [7,11] and
a significant delay and frequent initial misdiagnosis occur
in most patients with Lewy body dementia [7,8]. The
LBCRS has the potential to provide a clearer, more
accurate picture for those patients who are unable to be
seen by specialists, hastening the correct diagnosis and
reducing the strain and burden placed on patients and
caregivers [8–10,48]. Improving sensitivity of diagnoses
also (1) reduces the risk of exposure in DLB patients to
medications that can have potentially serious adverse
consequences (i.e., neuroleptics); (2) increases the
potential opportunity to receive appropriate symptomatic
therapies in a timely fashion; and (3) lessens the
inappropriate exclusion from and inclusion into clinical
trials [12].
The LBCRS exhibits excellent data quality including
item and scale score variability with ample dispersion
of scores. The LBCRS demonstrated excellent internal
consistency, known-group validity, and discrimination
to distinguish between DLB, AD, and other dementias.
Furthermore, the LBCRS was able to discriminate
between MCI due to different underlying etiologies
(DLB vs. AD). Based on post hoc tests, the motor and
nonmotor subdomains equally discriminated group mem-
bership. Use of the LBCRS can significantly improve
ability to diagnose and classify dementia syndromes
thought to be attributable to Lewy body pathology,improve clinical detection, and facilitate enrollment for
clinical trials.
A number of “gold standard” evaluations for determining
dementia etiology exist including detailed neuropsycholog-
ical evaluations as the profile of cognitive deficits appears to
be different between dementia etiologies [5]. In particular,
DLB differs from AD by earlier and greater involvement
in visuospatial, executive, and attention domains [5,49].
Although commonly used by neuropsychologists for
diagnosis and as outcomes for clinical research projects,
comprehensive neuropsychological testing requires a well-
trained clinician and ample time to conduct the testing and
may not be readily available for all patients. It is interesting
to note that in the present study a battery of neuropsycholog-
ical tests established a cognitive impairment but did not indi-
vidually provide differentiation between DLB and AD [50]
or betweenMCI due to DLB versusMCI due to AD, whereas
clinical signs and symptoms provided discrimination
[15,51,52].
The LBCRS was developed and validated in the
context of a memory disorders center where the preva-
lence of MCI and dementia is high. Validation of the
LBCRS in other settings where dementia prevalence is
lower (e.g., community samples, primary care practices)
is a reasonable next step. The internal consistency of the
LBCRS was in the good to very good range suggesting
that it may be most suitable for group-based discrimina-
tion. The internal consistency is marred somewhat by
the diverse nature of the questions of the LBCRS (partic-
ularly nonmotor) reflecting the varied presentation of the
disorder (the 10 symptoms present in 7%–91% of pa-
tients). As this is a cross-sectional study, another next
step is to demonstrate the longitudinal properties of the
LBCRS and determine whether those individuals with
MCI due to DLB in fact develop DLB. Strengths of this
study included the comprehensive cognitive-behavioral-
motor evaluation and that the LBCRS was not used in
the diagnosis. Another advantage of the LBCRS is that
it is brief enough to be printed on one piece of paper or
viewed in on single computer screenshot which should
maximize its clinical utility. In establishing the validity
and reliability of the LBCRS, we wanted to test its perfor-
mance in a “real-world” clinic setting with patients who
are referred from the community rather than in a research
sample. Our clinic sample had an admixture of gender,
education, comorbidities, cognitive, behavioral, affective,
J.E. Galvin / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 316-324 323motor symptoms, and diagnoses. A limitation was that the
diagnoses were largely clinical based on published
criteria, no biomarkers or pathology was considered in
this project. As this was a clinical research project, bio-
markers such as dopamine transporter scans are not
FDA-approved for diagnosing DLB in the United States.
However, the LBCRS was developed from autopsy-
verified cases of health controls, AD, Parkinson’s disease,
PDD, and DLB [15] and validated in a research sample
with AD biomarkers [14]. There were no PDD cases
included in this study for two reasons: (1) PDD would
by definition have a positive LBCRS because the four
cardinal motor signs of Parkinson’s disease (bradykinesia,
rigidity, postural instability, and rest tremor) and (2)
many of these patients are predominantly seen by the
movement disorders specialist at academic centers rather
than by cognitive specialists. The published LBCRS
studies to date have been completed at a single site; future
studies at other sites by other investigators are needed
to further demonstrate utility; however, a recent presenta-
tion reported the validity of the LBCRS discriminating
AD from DLB in a sample of Korean older adults with
dementia [53].
The LBCRS may serve as an effective clinical research
tool to improve the detection of DLB (and PDD) in the of-
fice setting, assist in the inclusion/exclusion criteria for
clinical trials, and as an intermittent assessment tool to
determine whether the DLB phenotype is developing.
Early detection of Lewy body dementias will be important
to enable future interventions at the earliest stages when
they are likely to be most effective. This study provides
evidence-based methodology to use the LBCRS to iden-
tify individuals likely to have Lewy bodies at autopsy in
clinical practice and for participation in clinical trials,
prevention studies, community surveys, and biomarker
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1. Systematic review: The author reviewed the litera-
ture using traditional (e.g., PubMed) sources.
Although consensus criteria for dementia with
Lewy bodies exist and have excellent specificity
(79%–100%), in clinical practice, the criteria have
poor sensitivity (12%–88%). This is in part due the
lack of a standardized way to operationalize the
core, suggestive and supportive features in a way
that lends itself to clinical practice outside of spe-
cialty centers. To address this, we created and vali-
dated the Lewy body composite risk score (LBCRS).
2. Interpretation: Our findings support the LBCRS may
provide a rapid method to determine the probability
that Lewy body pathology is a significant contributor
to the dementia syndrome and should facilitate eligi-
bility for clinical trials and research projects, stage
patients in clinical practice, and improve case ascer-
tainment and staging in population studies.
3. Future directions: The LBCRS is robust in detecting
dementia and cognitive impairment due to Lewy
body pathology in a clinical sample. Future studies
are needed to assess the utility of the LBCRS in other
settings where dementia prevalence is lower (com-
munity cohort and primary care), examine the longi-
tudinal properties of the LBCRS, and test its
response to interventions.
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